Dr. Reba Rabenstein advises clients regarding complex intellectual property and trade secret litigation, arbitration, and strategy across industries, with a particular focus on leading branded pharmaceutical and biotechnology companies.

Dr. Rabenstein is a seasoned trial attorney representing clients at all stages of litigation, including pre-suit investigation, litigation, trial, and appeal. She has gone to trial in multiple district courts, including the District of Delaware, the Southern District of New York, and in the District of Massachusetts, where she participated in the first virtual patent trial in that district.

Having worked both for patentees and patent defendants, Dr. Rabenstein helps her clients strategically navigate cutting-edge legal issues to achieve successful outcomes.

For pharmaceutical and biotechnology companies, she regularly handles cases involving:

  • Regenerative medicine
  • Gene therapy
  • Molecular biological techniques
  • Small molecule pharmaceuticals

Drawing on her academic experience in cellular and molecular biology, physiology, and pharmacology, she is well-positioned to understand the science and translate it to judges and juries. In addition, Dr. Rabenstein leverages her litigation experience to advise clients on due diligence matters and business strategies regarding intellectual property.

Prior to joining Latham, Dr. Rabenstein served as a law clerk to Chief Judge Kimberly A. Moore of the United States Court of Appeals for the Federal Circuit. She earned her JD from the University of Michigan Law School, where she served as executive note editor of the Michigan Telecommunications and Technology Law Review.

As a result of her graduate and undergraduate research and various collaborative efforts, Dr. Rabenstein has co-authored several scientific articles.

Dr. Rabenstein’s representative experience includes:

  • Astellas Institute for Regenerative Medicine v. ImStem Biotechnology, Inc., et al. (D. Mass.) — represented Astellas in a correction of inventorship suit regarding Astellas’ breakthrough technology for generating human mesenchymal stem cells; successfully sought summary judgment adding Astellas’ scientists as inventors on patents filed by defendants; following a 2.5 week virtual trial, successfully sought removal of defendants as inventors on the patents they filed, and fended off defendants’ attempts to be added as inventors on Astellas’ patents
  • AbbVie v. Novartis Vaccines and Diagnostics (N.D. Cal. & Arbitration) — successfully represented AbbVie in a dispute related to Hepatitis C Virus patents and treatments
  • Pacific Coast Bldg. Prods., Inc. v. CertainTeed Gypsum, Inc. (Fed. Cir.; N.D. Cal; W.D. Ark.): Represented CertainTeed in multi-patent cases relating to gypsum and viscoelastic glue products. Invalidated one patent based on indefiniteness, which was affirmed on appeal, and obtained dismissal with prejudice for all other patents
  • A branded pharmaceutical company in Hatch-Waxman litigation against several defendants, including discovery, pretrial, claim construction, three trials, and multiple settlements*
  • A branded pharmaceutical company in Hatch-Waxman litigation involving a dermatological product, including pretrial, claim construction, and trial*
  • Individuals seeking asylum in the United States in a pro bono matter*

*Matter handled prior to joining Latham

Bar Qualification

  • District of Columbia
  • New York
  • US Patent and Trademark Office


  • JD, University of Michigan Law School
    cum laude
  • PhD in Neuroscience (Molecular Psychiatry), Yale University
  • MPhil in Neuroscience (Molecular Psychiatry), Yale University
  • BS in Psychobiology, The Ohio State University
    magna cum laude, Phi Beta Kappa, With Distinction, With Honors
General Recognition Thumbnail
February 13, 2021 Recognition

Law Firm of the Week: Latham & Watkins

Latham honored for a huge trade secrets win for LG Energy Solution at the US International Trade Commission, a significant patent trial victory for Astellas, and the strength of the firm's global Private Equity Practice.